PFIZER REPORTS THIRD-QUARTER 2015 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cowen Remains Positive as Pfizer (PFE) Reports a 3Q Beat and raise
October 27, 2015 4:23 PM EDTCowen reiterated an Outperform rating and $43.00 price target on Pfizer (NYSE: PFE) following the company's 3Q earnings results. Q3 sales of $12,087MM (-2%) were $527MM above consensus. EPS of $0.60 (+5%) was $0.09 ahead of consensus. 2015 EPS guidance was raised to $2.16-2.20 from prior $2.04-2.10 range.... More
Pfizer (PFE) Tops Q3 EPS by 9c
October 27, 2015 6:46 AM EDTPfizer (NYSE: PFE) reported Q3 EPS of $0.60, $0.09 better than the analyst estimate of $0.51. Revenue for the quarter came in at $12.1 billion versus the consensus estimate of $11.56 billion.
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our business continues to demonstrate strength across key product lines and geographies which has resulted in another quarter of strong financial performance. We have been intently focused on seeking to generate a greater portion of our earnings from increased revenues and I see our product portfolio, product pipeline and recent business development activity as... More
